secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001628280-23-005562
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept reports Q4 revenue $103.1M, FY 2022 revenue $401.9M; guides 2023 revenue $430-450M
--------------------------------------------------------------------------------

- Q4 2022 revenue $103.1M vs $98.8M Q4 2021; FY revenue $401.9M vs $366.0M.
- FY 2022 diluted EPS $0.87 vs $0.89 in 2021; net income $101.4M vs $112.5M.
- Cash and investments $436.6M at Dec 31, 2022, up from $335.8M year-end 2021.
- NDA for relacorilant in Cushing's syndrome expected Q1 2024; GRACE enrollment closing.
- Phase 3 ROSELLA (ovarian cancer) and Phase 2 DAZALS (ALS) enrolling; miricorilant Phase 1b NASH data mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/0001628280-23-005562-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023005562/cort-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005562

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer